Table 3.

Key recommendations

Challenges	Requirements
Improvement and refinement in describing fibrosis	Describe species, genetic background, perturbation, background therapies Describe disease and time point where analyses were done Describe quantity and quality of fibrosis Describe culprit cells and associated (glyco‐) proteins
Improvement in detecting fibrosis	Need for better imaging tools Need for cardio‐specific biomarkers with relation to myocardial fibrosis Improvement in ‐omics to better pinpoint key factors that drive fibrosis
Targeting fibrosis	Gain precise awareness of what element at what time point may be targeted Novel (designer) drugs affecting deleterious fibrosis